Arbutus to Participate in Two Upcoming Investor Conferences

Core Viewpoint - Arbutus Biopharma Corporation is actively engaging with investors through participation in two upcoming conferences, highlighting its focus on developing a functional cure for chronic hepatitis B virus (cHBV) infection [1][2]. Group 1: Company Overview - Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company specializing in virology, aiming to develop novel therapeutics for chronic hepatitis B virus (cHBV) [2]. - The company’s strategy involves suppressing HBV DNA, reducing surface antigen, and enhancing HBV-specific immune responses to achieve a functional cure [2]. - Arbutus has a pipeline that includes proprietary compounds such as imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor [2]. Group 2: Clinical Trials - Imdusiran is currently undergoing two Phase 2a combination clinical trials, showing promising clinical data in reducing surface antigen and reawakening HBV-specific immune responses [2]. - AB-101 is in the Phase 1a/1b clinical trial stage, indicating ongoing development efforts for this compound [2]. Group 3: Investor Engagement - The management team of Arbutus will present at the Barclays 26th Annual Global Healthcare Conference on March 12, 2024, and will also participate in the Jefferies Biotech on the Bay Summit on March 13, 2024 [1]. - A live webcast of the Barclays conference presentation will be available, with an archived replay accessible on the Arbutus website for a limited time [1].